Form D · Biotechnology
CESSATION THERAPEUTICS, INC.
Dallas, TX · CIK 0001926434
Offering snapshot reported Apr 3, 2024 · SEC filing
- Reported sold
- $1M Offering amount: $1M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 29, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 3, 2024 | Initial | $1,000,000 | No comparison | 2 | SEC filing |
| May 11, 2022 | Initial | $5,755,000 | No comparison | 31 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-509539
Source: Form D, filed Apr 3, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andrew Barrett | Executive |
| Daniel Fine | Director |
| David Genecov | Director |
| John Harkey | Director |
| Mark Pearson | Director |
| Eric Rasmussen | Executive |
| Jay Shepard | Director |
| Sharon Tetlow | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
12200 Stemmons Freeway Suite 100
Dallas, TX, 75234
Dallas, TX, 75234